Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Crestor Adverse Events Comparable to Zocor In Statin Safety Report

Executive Summary

AstraZeneca's Crestor falls in the middle of the statin pack in terms of class-related adverse events in actual practice, according to preliminary results of a claims database analysis by the National Lipid Association

You may also be interested in...



FDA Safety Data-mining In Literature To Start With Fluoroquinolones, Lipid Drugs

The agency is seeking a contractor to develop a tool to examine the National Library of Medicine’s MEDLINE database of biomedical articles, with pilot studies that seemed aimed at quantification of already-know risks.

High-Dose Lipitor Is As Safe As Lower Doses, Pfizer Analysis Finds

Treatment-related adverse events for Lipitor 80 mg were similar to those for atorvastatin 10 mg, according to a Pfizer analysis of pooled studies of the cholesterol-lowering drug reported in the January issue of the American Journal of Cardiology

High-Dose Lipitor Is As Safe As Lower Doses, Pfizer Analysis Finds

Treatment-related adverse events for Lipitor 80 mg were similar to those for atorvastatin 10 mg, according to a Pfizer analysis of pooled studies of the cholesterol-lowering drug reported in the January issue of the American Journal of Cardiology

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS046114

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel